19725-80-5

Upstream product

• 67-56-1 methanol 
• 19722-72-6 (4-Chlor-2-methoxycarbonyl-phenyl)-diazomethyl-keton 
• 64481-29-4 2-methoxycarbonylmethyl-5-amino-benzoic acid methyl ester 
• 118-45-6 4-chlorophthalic anhydride 
• 89-51-0 Homophthalic acid 
• 95-13-6 1-indene 
• 64481-28-3 2-methoxycarbonylmethyl-5-nitro-benzoic acid methyl ester 
• 3898-66-6 2-(carboxymethyl)-5-nitrobenzoic acid 

Downstream Products

• 1421604-87-6 2-(4-chloro-2-methoxycarbonyl-phenyl)-2-bromo-acetic acid methyl ester 
• 19725-81-6 4-chlorohomophthalic acid 

Relevant academic research and scientific papers

HCV PROTEASE INHIBITORS

The present invention discloses a compound of general formula (I); A is O, S, CH, NH or NR', when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C-Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or -Y1-Rm; A1 is NH or CH2; R1' is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalky etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.

HCV Protease Inhibitors

A compound of general formula (I); A is O, S, CH, NH or NR′, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1′ is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.